A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder
Mathew SJ, Gueorguieva R, Brandt C, Fava M, Sanacora G. A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder. Neuropsychopharmacology 2017, 42: 2567-2574. PMID: 28553836, PMCID: PMC5686483, DOI: 10.1038/npp.2017.106.Peer-Reviewed Original ResearchConceptsMajor depressive disorderSecondary efficacy outcomesEfficacy outcomesNeuroprotective effectsDepressive disorderResponse rateTreatment-resistant major depressive disorderMontgomery-Åsberg Depression Rating ScaleClinical Global Impressions-SeverityCurrent major depressive episodeDose of riluzolePlacebo/placeboSafety of riluzoleFixed-dose trialTreatment-resistant depressionSide effect profileGlutamate-modulating agentsMajor depressive episodeDepression Rating ScaleLack of efficacyPatient-reported measuresAmyotrophic lateral sclerosisSequential parallel comparison designRiluzole effectsAntidepressant efficacy